Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Cancel Anytime
Enjoy Unlimited Digital Access
Canada’s most-awarded
newsroom for a reason
Stay informed for a
lot less, cancel anytime
“Exemplary reporting on
COVID-19” – Herman L
$1.99
per week
for 24 weeks
Get full access to globeandmail.com
Just $1.99per week for the first 24weeks
Just $1.99per week for the first 24weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

A Loblaws store is seen Monday, March 9, 2015 in Montreal.

Ryan Remiorz/The Canadian Press

Pharmacy owners are bracing for "an industry-wide impact" from lower generic drug prices coming in April, the CEO of Metro Inc., which has a deal to buy Quebec's largest pharmacy chain, said Tuesday.

The pan-Canadian Pharmaceutical Alliance – which represents the provincial, territorial and federal governments, and the Canadian Generic Pharmaceutical Association – announced Monday that they have reached an agreement that will see the prices of nearly 70 commonly prescribed generic drugs discounted by up to 90 per cent of their brand name equivalents.

"There will be an impact on sales as prices go down," said Metro chief executive Eric La Fleche Tuesday after the company's annual general meeting.

Story continues below advertisement

"It's an industry wide-impact," he said, noting the effect on his company will be much smaller as its presence in Ontario is smaller than Quebec, where a similar agreement was reached last year.

The company operates 74 drugstores in Ontario and 184 in Quebec. Its pharmaceutical network will grow further after its purchase of pharmacy chain Jean Coutu Group Inc., which is expected to close this spring.

"We're concerned by any impact," La Fleche said.

The company's shares were relatively unchanged after markets closed, down 0.3 per cent to $40.75, on the same day the Montreal-based retailer announced a nearly 11 per cent boost to its quarterly dividend after profits surged in the first quarter.

Meanwhile, Loblaw, which owns the Shoppers Drug Mart chain, saw its stock downgraded once details of the drug reform emerged. Its shares fell more than three per cent Tuesday.

Desjardins Group lowered its target price for the grocery-and-pharmacy retailer to $76 per share, from $84, and cut its recommendation to hold.

"Loblaw has experienced a confluence of headwinds," wrote Keith Howlett, an analyst with Desjardins Capital Markets in a note Tuesday. He pointed to a $190-million impact due to rising minimum wage, somewhere between $75-million and $150-million in initial costs to address its participation in an alleged industry-wide bread price-fixing scandal, and the impact of drug reform.

Story continues below advertisement

Desjardins estimates drug reform will add $220-million in costs for Loblaw.

The severity of the reduction in generic drug prices announced earlier this week is at the high end of the range that the industry expected, wrote Irene Nattel, an analyst with RBC Dominion Securities Inc. She dropped her target price to $84, from $87.

Loblaw shares shed 3.16 per cent to $67.03 after reaching a daily low of $65.98 Tuesday on the Toronto Stock Exchange.

The company had started to implement measures to mitigate the impending drug reform, but until Monday the details of the plan were unclear, said Nattel, pointing out the benefit of removing that uncertainty.

Loblaw declined to comment, but management has previously noted the possible impact of generic drug pricing changes.

Loblaw expected additional health-care reform to significantly impact its pharmacy business, Richard Dufresne, Loblaw's then-chief financial officer, said during the company's third-quarter conference call in November.

Story continues below advertisement

No single initiative will offset "the significant industry headwinds," he said, but the company has made progress to mitigate them.

"But, depending on how health-care reform plays out, we expect we have not covered all of it."

Report an error
Tickers mentioned in this story
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.
Comments are closed

We have closed comments on this story for legal reasons or for abuse. For more information on our commenting policies and how our community-based moderation works, please read our Community Guidelines and our Terms and Conditions.

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies